Date | Price Target | Rating | Analyst |
---|---|---|---|
9/27/2024 | $16.00 | Neutral → Buy | UBS |
4/10/2024 | $23.00 | Sector Weight → Overweight | KeyBanc Capital Markets |
4/4/2024 | Mkt Perform | JMP Securities | |
2/26/2024 | $19.00 | Market Perform | Leerink Partners |
12/7/2023 | $17.00 | Neutral | UBS |
12/5/2023 | Sector Weight | KeyBanc Capital Markets | |
8/22/2023 | $24.50 → $17.00 | Buy → Hold | Jefferies |
8/10/2023 | Outperform → Mkt Perform | William Blair |
RADNOR, Pa., Oct. 02, 2024 (GLOBE NEWSWIRE) -- Certara, Inc. (NASDAQ:CERT), a global leader in model-informed drug development, today announced it has completed the acquisition of Chemaxon. Chemaxon develops leading scientific informatics software products used by the life sciences industry for in-silico research. Certara develops advanced modeling and biosimulation solutions used to predict the pharmacokinetic and pharmacodynamic properties of large and small molecules. "Combining Chemaxon's expertise with Certara's biosimulation capabilities provides life sciences companies with unique solutions to enhance productivity and increase their scientific innovation success rates," said Willi
RADNOR, Pa., Sept. 24, 2024 (GLOBE NEWSWIRE) -- Certara, Inc. (NASDAQ:CERT), a global leader in model-informed drug development, today announces the celebration of the 25th anniversary of the Simcyp® Consortium. The Simcyp Consortium has become a global authority on mechanistic physiologically-based pharmacokinetic (PBPK) modeling and simulation. With members from 35 leading biopharmaceutical companies, the Simcyp® Consortium was created to guide the development of best practices, identify the most critical use areas, and fill the scientific gaps that were needed for studying drug handling by the body in computer-generated, virtual patients and beyond the limited framework of clinical tri
RADNOR, Pa., Sept. 18, 2024 (GLOBE NEWSWIRE) -- Certara, Inc. (NASDAQ:CERT), a global leader in model-informed drug development, today shared the results from its collaboration with Ichnos Glenmark Innovation (IGI) on the first-in-human dose prediction and selection for ISB 2001. IGI's drug candidate is a trispecific T-cell engager (TCE) being studied as a potential cancer treatment. Preclinical research and biosimulation findings were recently published in Nature Cancer. This publication highlighted ISB 2001's therapeutic potential for relapsed/refractory multiple myeloma patients. Difficulties translating data from animals to patients traditionally limit first-in-human (FIH) dose sele
4 - Certara, Inc. (0001827090) (Issuer)
4 - Certara, Inc. (0001827090) (Issuer)
4 - Certara, Inc. (0001827090) (Issuer)
RADNOR, Pa., Oct. 02, 2024 (GLOBE NEWSWIRE) -- Certara, Inc. (NASDAQ:CERT), a global leader in model-informed drug development, today announced it has completed the acquisition of Chemaxon. Chemaxon develops leading scientific informatics software products used by the life sciences industry for in-silico research. Certara develops advanced modeling and biosimulation solutions used to predict the pharmacokinetic and pharmacodynamic properties of large and small molecules. "Combining Chemaxon's expertise with Certara's biosimulation capabilities provides life sciences companies with unique solutions to enhance productivity and increase their scientific innovation success rates," said Willi
RADNOR, Pa., Aug. 06, 2024 (GLOBE NEWSWIRE) -- Certara, Inc. (NASDAQ:CERT), a global leader in model-informed drug development, today reported its financial results for the second quarter of fiscal year 2024. Second Quarter Highlights: Revenue was $93.3 million, compared to $90.5 million in the second quarter of 2023, representing growth of 3%. Software revenue was $38.2 million, compared to $33.7 million in the second quarter of 2023, representing growth of 13%.Services revenue was $55.1 million, compared to $56.7 million in the second quarter of 2023, representing a decline of 3%. Net loss was $12.6 million, compared to a net income of $4.7 million in the second quarter of 2023.Adjuste
RADNOR, Pa., July 02, 2024 (GLOBE NEWSWIRE) -- Certara, Inc. (NASDAQ:CERT), a global leader in model-informed drug development, today announced that it will release financial results for the second quarter of 2024 after the market close on Tuesday, August 6th, 2024. Company management will host a conference call to discuss financial results at 5:00PM ET. Investors interested in listening to the conference call are required to register online. It is recommended to register at least one day in advance. A live and archived webcast of the event will be available on the "Investors" section of the Certara website at https://ir.certara.com/. About CertaraCertara accelerates medicines using bio
144 - Certara, Inc. (0001827090) (Subject)
10-Q - Certara, Inc. (0001827090) (Filer)
8-K - Certara, Inc. (0001827090) (Filer)
SC 13G/A - Certara, Inc. (0001827090) (Subject)
SC 13G/A - Certara, Inc. (0001827090) (Subject)
SC 13G/A - Certara, Inc. (0001827090) (Subject)
RADNOR, Pa., May 21, 2024 (GLOBE NEWSWIRE) -- Certara, Inc. (NASDAQ:CERT), a global leader in model-informed drug development, has appointed Rona Anhalt as Chief Human Resources Officer and Daniel Corcoran as General Counsel. "Rona and Daniel are leaders in their fields. They have proven track records of growing teams and building high-performing businesses," said William F. Feehery Ph.D., CEO, Certara. "I'm confident they will further Certara's mission of accelerating medicines to patients through the delivery of solutions that improve the entire drug research and development process." Ms. Anhalt will drive Certara's human capital management strategy. She will lead the company's global
PRINCETON, N.J., July 25, 2022 (GLOBE NEWSWIRE) -- Certara, Inc. (NASDAQ:CERT), a global leader in biosimulation, today announced the appointment of Rosemary Crane to its Board of Directors, effective July 21, 2022. Her appointment brings the company's board of directors to eleven members. "We are excited to welcome an accomplished business leader with a proven track record of success join Certara's Board," said William F. Feehery, PhD, CEO of Certara. "Rose's experience in executive leadership and expertise in commercialization will provide immense value as the Company grows its impact on the biopharmaceutical industry worldwide." Ms. Crane has more than 35 years of experience in the ph
PRINCETON, N.J., July 13, 2022 (GLOBE NEWSWIRE) -- Certara, Inc. (NASDAQ:CERT), a global leader in biosimulation, today announced the appointment of Eran Broshy to its Board of Directors, effective July 11, 2022. His appointment brings the company's board of directors to ten members. "Eran has a proven track record taking high-growth healthcare businesses to the next level and delivering superior results," said William Feehery, Ph.D., CEO of Certara. "Certara is excited to have someone of his caliber and experience join the board. I look forward to Eran's contribution in guiding us as we grow our impact by informing critical decisions in drug development with biosimulation, technology and
UBS upgraded Certara from Neutral to Buy and set a new price target of $16.00
KeyBanc Capital Markets upgraded Certara from Sector Weight to Overweight and set a new price target of $23.00
JMP Securities initiated coverage of Certara with a rating of Mkt Perform
Keybanc analyst Scott Schoenhaus maintains Certara (NASDAQ:CERT) with a Overweight and lowers the price target from $23 to $20.
JMP Securities analyst Constantine Davides reiterates Certara (NASDAQ:CERT) with a Market Perform.
Certara, excluding Chemaxon, is reiterating 2024 revenue, adjusted EBITDA margin, and adjusted diluted earnings per share guidance consistent with the May 7th earnings call. Following transaction close, Certara will update its 2024 guidance to include contribution from Chemaxon and expects to maintain its 2024 adjusted EBITDA margin guidance of 31-33%.